Cited by 373Gastrointestinal motility and disordersPelvic floor disorders treatmentsCongenital gastrointestinal and neural anomalies

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Two Randomized Trials of Linaclotide for Chronic Constipation

Open access

Lembo, Anthony J., Schneier, Harvey A., Shiff, Steven J., Kurtz, Caroline B., MacDougall, James E., Jia, Xinwei D., Shao, James Z., Lavins, Bernard J., Currie, Mark G., Fitch, Donald A., Jeglinski, Brenda I., Eng, Paul, Fox, Susan M., Johnston, Jeffrey M.·2011·New England Journal of Medicine

DOI 10.1056/nejmoa1010863

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Linaclotide is a minimally absorbed peptide agonist of the guanylate cyclase C receptor. In two trials, we aimed to determine the efficacy and safety of linaclotide in patients with chronic constipation. METHODS: We conducted two randomized, 12-week, multicenter, double-blind, parallel-group, placebo-controlled, dual-dose trials (Trials 303 and 01) involving 1276 patients with chronic constipation. Patients received either placebo or linaclotide, 145 μg or 290 μg, once daily for 12 weeks. The primary efficacy end point was three or more complete spontaneous bowel movements (CSBMs) per week and an increase of one or more CSBMs from baseline during at least 9 of the 12 weeks. Adverse events were also monitored. RESULTS: For Trials 303 and 01, respectively, the primary end point was reached by 21.2% and 16.0% of the patients who received 145 μg of linaclotide and by 19.4% and 21.3% of the patients who received 290 μg of linaclotide, as compared with 3.3% and 6.0% of those who received placebo (P<0.01 for all comparisons of linaclotide with placebo). Improvements in all secondary end points were significantly greater in both linaclotide groups than in the placebo groups. The incidence of adverse events was similar among all study groups, with the exception of diarrhea, which led to discontinuation of treatment in 4.2% of patients in both linaclotide groups. CONCLUSIONS: In these two 12-week trials, linaclotide significantly reduced bowel and abdominal symptoms in patients with chronic constipation. Additional studies are needed to evaluate the potential long-term risks and benefits of linaclotide in chronic constipation. (Funded by Ironwood Pharmaceuticals and Forest Research Institute; ClinicalTrials.gov numbers, NCT00765882 and NCT00730015.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1010863

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Stool form scale as a useful guide to intestinal transit time
Lewis, S. J., & Heaton, K. W. (1997) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529709011203 · Cited by 3,244
Epidemiology of Constipation in North America: A Systematic Review
Higgins, P., & Johanson, J. (2004) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.04114.x · Cited by 1,048
Chronic Constipation
Lembo, A., & Camilleri, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020995 · Cited by 692
Self-citation
Chronic constipation: a survey of the patient perspective
JOHANSON, J. F., & KRALSTEIN, J. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03238.x · Cited by 617
Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire
Marquis, P., de la Loge, C., Dubois, D., Mcdermott, A., & Chassany, O. (2005) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520510012208 · Cited by 586
Heat-stable enterotoxin of Escherichia coli: in vitro effects on guanylate cyclase activity, cyclic GMP concentration, and ion transport in small intestine.
Field, M., Graf, L. H., Laird, W., & Smith, P. L. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.6.2800 · Cited by 561
AGA Medical Position Statement on the Diagnosis and Management of Colorectal Neoplasia in Inflammatory Bowel Disease
Farraye, F. A., Odze, R. D., Eaden, J., & Itzkowitz, S. H. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.037 · Cited by 530
An epidemiological survey of constipation in Canada: definitions, rates, demographics, and predictors of health care seeking
Paré, P., Ferrazzi, S., Thompson, W., Irvine, E. J., & Rance, L. (2001) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.05259.x · Cited by 445
The burden of constipation on quality of life: results of a multinational survey
Wald, A. M., Scarpignato, C., Kamm, M. A., Mueller‐Lissner, S., HELFRICH, I., Schuijt, C., Bubeck, J., Limoni, C., & Petrini, O. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03376.x · Cited by 374
Systematic Review on the Management of Chronic Constipation in North America
Brandt, L. J., Prather, C. M., Quigley, E. M. M., Schiller, L. R., Schoenfeld, P., & Talley, N. J. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.50613_2.x · Cited by 344

Flagged first, then by citations

Show all 18 references

Research works printed but not linked: 1

Martin BC, 2006, Manag Care Interface, 19, 43

Sorted by citations

Items 301–372 of 372

Clinical evidence for the role of linaclotide for the treatment of irritable bowel syndrome
Malagelada, J. (2012) · Clinical Investigation · doi:10.4155/cli.12.95 · Cited by 1
Linaclotide: a guanylate cyclase agonist for treatment of irritable bowel syndrome with constipation and chronic constipation in adults
Tikoo, D., & Gupta, M. (2013) · International Journal of Basic & Clinical Pharmacology · doi:10.5455/2319-2003.ijbcp20130323 · Cited by 1
6. Intractable Chronic Constipation
Ohkubo, H., & Nakajima, A. (2013) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.102.83 · Cited by 1
MANAGEMENT OF SLOW COLONIC TRANSIT CONSTIPATION IN PARKINSON’S DISEASE: CURRENT EVIDENCE AND A COMMUNITY PHARMACY PERSPECTIVE
Johnson, M., & Johnson, J. L. (2016) · Adelaide Research & Scholarship (AR&S) (University of Adelaide) · Cited by 1
VII. How to Treat Chronic Constipation with Intestinal Secretagogues or Inhibitor of Ileal Bile Acid Transporter
Fukudo, S., Endo, Y., & Kanazawa, M. (2019) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.108.46 · Cited by 1
Rationale and design of a multicenter, single-group, open-label trial aiming at investigating the effectiveness of elobixibat for loss of defecation desire in patients with chronic constipation
Yamamoto, A., Kessoku, T., Tanaka, K., Takahashi, K., Kasai, Y., Ozaki, A., Iwaki, M., Kobayashi, T., Yoshihara, T., Misawa, N., et al. (2022) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2022.100958 · Cited by 1
Pediatric Constipation: an Epidemiologic and Physiologic Approach to Guide a Stepwise Approach to its Management
Mousa, H. M., Barsamian, J. M., Benitez, A., Webster, J., & Fiorino, K. N. (2020) · Current Treatment Options in Pediatrics · doi:10.1007/s40746-020-00199-z · Cited by 2
Tratamiento del estreñimiento funcional en pediatría
Aguirre-Raya, K. A., Monjaráz, E. M. T., & Ramírez-Mayans, J. A. (2020) · NeuroGastroLATAM Reviews · doi:10.24875/ngl.19000039 · Cited by 1
Inconvenient topic: laxative abuse. review and clinical case
Konovalova, N. V., Стопінчук, О. В., & Крикус, О. Ю. (2020) · Reports of Vinnytsia National Medical University · doi:10.31393/reports-vnmedical-2020-24(4)-28 · Cited by 1
Large Intestine
Washabau, R. J., Gaschen, F. P., Allenspach, K., Gookin, J. L., & Holt, D. E. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-3661-6.00058-4 · Cited by 1
Clarification of Linaclotide Clinical Trial Information in a Recent Review on Constipation
Johnston, J. M., & Weissman, T. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.06.003 · Cited by 1
Self-citation
Management of patients with ‘refractory’ IBS: how to approach the patientMultiple choice questions
Athanasakos, E., & Emmanuel, A. V. (2013) · doi:10.2217/ebo.13.530 · Cited by 1
Corrigendum
(2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12353 · Cited by 1
Functional Constipation
Shin, J. E. (2022) · Springer eBooks · doi:10.1007/978-981-19-0120-1_17 · Cited by 2
Constipation de transit : les traitements ayant fait la preuve de leur efficacité
Zeitoun, J., & de Parades, V. (2011) · Côlon & Rectum · doi:10.1007/s11725-011-0331-4
Traitements médicaux des constipations
Sénéjoux, A. (2013) · Springer eBooks · doi:10.1007/978-2-8178-0356-2_28
Implementation of Gut-Directed Hypnotherapy for Irritable Bowel Syndrome In Clinical Practice
Lindfors, P. (2012) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Do We Know How to Manage Irritable Bowel Syndrome
Emmanuel, A. V. (2014)
Poverty and Slowness of Voluntary Movement
Martino, D., Espay, A. J., Fasano, A. A., & Morgante, F. (2015) · Springer eBooks · doi:10.1007/978-3-662-48468-5_1
New Drug Update: 2012
Hussar, D. A. (2013) · The Consultant Pharmacist · doi:10.4140/tcp.n.2013.210
Nytt middel mot kronisk obstipasjon
Jacobsen, G. W. (2011) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.11.1178
Dietary therapy for irritable bowel syndrome
Lebwohl, B., & Green, P. (2016) · British medical journal · doi:10.1136/bmj.i3902
FDA Approval Sought for Drug to Treat Chronic Constipation
Brett, A. S. (2011) · Journal watch · doi:10.1056/jw201109060000004
Irritable bowel syndrome pharmacotherapy
Camilleri, M. (2013) · doi:10.2217/ebo.13.456
The Pharmacological Management of Chronic Constipation and Faecal Incontinence
Kamperidis, N., & Arebi, N. (2016) · Springer eBooks · doi:10.1007/978-3-319-43214-4_11
Linaclotide in constipation-predominant irritable bowel syndrome and chronic idiopathic constipation: a profile of its use in the USA
McKeage, K., & Lyseng-Williamson, K. A. (2017) · Drugs & Therapy Perspectives · doi:10.1007/s40267-017-0448-0
“Table 3 Efficacy of oral linaclotide 145 lg once daily after 12 weeks of treatment in patients with chronic idiopathic constipation in two randomized, double-blind, phase 3 trials (Trials 3 and 4) [18]”
BackgroundMethodResultInfluential
Top 10 Drugs Most Commonly Used for GI Motility Disorders
Lomeli, L. D., Gaumnitz, E. A., & Reichelderfer, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-59352-4_39
Response to Miner et al.
Currie, M. G., Shiff, S. J., Schneier, H. A., & Johnston, J. M. (2017) · The American Journal of Gastroenterology · doi:10.1038/ajg.2017.362
Self-citation
Targeting cyclic GMP signaling for the treatment of gastrointestinal diseases
Sharman, S. K. (2017)
Newer agents for constipation: linaclotide
Badiali, D., Biviano, I., & Corazziari, E. S. (2013) · doi:10.2217/ebo.13.216
Recent Advances in the Diagnosis and Treatment for Chronic Constipation
Nakajima, A., Fuyuki, A., & Okubo, H. (2017) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.106.2453
Bi-specific immunotherapy for gastrointestinal malignancies
Baybutt, T. R., & Snook, A. E. (2020) · Digestive Medicine Research · doi:10.21037/dmr-20-79
“Currently, the GUCY2C signaling axis is pharmacologically targeted by US FDA-approved peptide therapeutics, linaclotide (Linzess™) and plecanatide (Trulance™), for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic idiopathic constipation (CIC) (3-5).”
Background
Comparative Efficacy of Linaclotide Versus Other Oral Constipation Treatments in Chronic Constipation: a Network Meta-analysis
Okumura, H., Tang, W., Iwasaki, K., Shoji, S., Odaka, T., & Nakajima, A. (2020) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-020-00467-x
“[59] CC Arm 1 Linaclotide 145 μg 213 3.”
Background
Managing functional constipation: the course doesn’t always run smooth
Fenton, C., & Kang, C. (2021) · Drugs & Therapy Perspectives · doi:10.1007/s40267-020-00803-0 · Cited by 1
Pharmacological Treatments for Constipation and Opioid-Induced Constipation
Camilleri, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00009-8
Effects of Laser Acupuncture on Constipation in Patients With Advanced Cancer: Study Protocol for a Double-blinded, Randomized Controlled TrialPreprint
Chen, J.-M., Chen, C., Wu, B.-Y., Chen, Y., & Liu, C. (2021) · Research Square · doi:10.21203/rs.3.rs-618552/v1
Chronic constipation: modern view on the problem. A review
Leshchyshyn, I. M., Susak, Y. M., Okhotska, O. I., Byk, P. L., Markulan, L. Y., & Панчук, О. В. (2021) · General Surgery · doi:10.30978/gs-2021-1-67 · Cited by 1
“But the problem arises as a result of lack of objective biological markers for FC and IBS-C.”
Influential
Estreñimiento
Ndam, A. N., Melchior, C., & Ducrotté, P. (2018) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(18)91413-3
Laxatives and Other Drugs for Constipation
Canning, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65642-8
Costipazione
Ndam, A. N., Melchior, C., & Ducrotte, P. (2018) · EMC - AKOS - Trattato di Medicina · doi:10.1016/s1634-7358(18)91692-x
Treatment
Marušić, M., Perić, R. T., & Karaula, N. T. (2018) · Clinical gastroenterology · doi:10.1007/978-3-319-75856-5_15
Constipation
Wald, A. M. (2016) · doi:10.1002/9781119127437.ch40
Estreñimiento
Bechiarelli, A. A., Romero, M. T. R.-C., Guerrero, P. P., & Ramos, C. R. (2016) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2016.03.010
Observational study: determinants for vegetable consumption among elementary school students in Indonesia
Sofianita, N. I., Khomsan, A., Setiawan, B., Ekayanti, I., & Octaria, Y. C. (2022) · F1000Research · doi:10.12688/f1000research.124754.1
“The negative health impact of skipping vegetables are not immediately evident, but the long-term effect can lead to various degenerative diseases, such as obesity,(10) hypertension,(11) cancer,(12) diabetes,(13) cardiovascular diseases,(14) and digestive problems.(15)”
Background
Effect of Bifidobacterium bifidum G9-1 on fecal short chain fatty acids in patients with chronic constipation: a multicenter, observational studyPreprint
Ogata, T., Kessoku, T., Jono, T., Kasai, Y., Ozaki, A., Tanaka, K., Takahashi, K., Yamamoto, A., Iwaki, M., Kobayashi, T., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2001863/v1
From healthy defecation to functional constipation in children and adults : a clinical and microbiological perspective
Wegh, C. A. M. (2022) · doi:10.18174/576006
Functional Constipation in Children
Wegh, C. A. M., & Benninga, M. A. (2022) · Springer eBooks · doi:10.1007/978-3-031-15229-0_41
Pediatric and adolescent GI motility disorders and management
Lu, P. L., Bali, N., & Lorenzo, C. D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-13911-6.00030-x
A review article on role of plecanatide drug in irritable bowel syndrome with constipation and chronic idiopathic constipation
Sharma, C., & Badyal, D. K. (2024) · National Journal of Pharmacology and Therapeutics · doi:10.4103/njpt.njpt_3_24
Meteorism and abdominal distension
Joksimović, Z., Bastać, D., & Pavlović, S. (2024) · Timocki medicinski glasnik · doi:10.5937/tmg2401014j
cDNA Display Selection of Interacting Peptide Ligands of the Guanylate Cyclase C Receptor
Ochiai, E., Takahashi, Y., Inokuchi, S., Sumiya, A., & Hasegawa, M. (2024) · Journal of Peptide Science · doi:10.1002/psc.3663
Drug Therapies for Non-motor Symptoms and Gut PD
Triadafilopoulos, G. (2024) · Springer eBooks · doi:10.1007/978-3-031-77171-2_6
Functional Constipation and Fecal Incontinence
de Geus, A., Jonker, C. A. L., van der Zande, J. M. J., & Benninga, M. A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-11760-2.00011-2
Additional file 1 of Comparative profiles of lubiprostone, linaclotide, and elobixibat for chronic constipation: a systematic literature review with meta-analysis and number needed to treat/harm
Rao, S. S., Manabe, N., Karasawa, Y., Hasebe, Y., Nozawa, K., Nakajima, A., & Fukudo, S. (2024) · Figshare · doi:10.6084/m9.figshare.26658436
Additional file 2 of Comparative profiles of lubiprostone, linaclotide, and elobixibat for chronic constipation: a systematic literature review with meta-analysis and number needed to treat/harm
Rao, S. S., Manabe, N., Karasawa, Y., Hasebe, Y., Nozawa, K., Nakajima, A., & Fukudo, S. (2024) · Figshare · doi:10.6084/m9.figshare.26658439
Know Your Guidelines Series: The ACG and AGA Guideline on Management of Constipation
Adla, A., Jackson, C. D., & Narayanan, S. (2026) · Southern Medical Journal · doi:10.14423/smj.0000000000001928
Gastrointestinal diseases: Sex and gender evidence in irritable bowel syndrome, liver lesions, gastroesophageal reflux, and inflammatory bowel disease
Sehgal, P., & Choudhary, C. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-26712-3.00005-7
Congrong Runtong oral liquid for functional constipation: A multicenter, placebo-controlled phase II trial
Zhao, L., Sun, X., Zhu, L., Chen, B., Qin, D., Fang, S., Gao, J., Liu, C., Wu, H., Liu, F., et al. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.157991
Vagal Nerve Stimulation for Chronic Constipation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Saleh, A. O., Awashra, A., Abouelmagd, A. A., Elkholy, M., Hasanin, E. H., Aldohni, A. A. A., Elkhattib, I., Abuelazm, M. T., & Elnaggar, M. (2026) · Neuromodulation Technology at the Neural Interface · doi:10.1016/j.neurom.2026.01.005 · Cited by 1
Pharmacological management of childhood constipation: Bridging today’s gaps with tomorrow’s therapies
Rajindrajith, S., Hathagoda, W., Balakrishnan, K., & Devanarayana, N. M. (2026) · World Journal of Clinical Pediatrics · doi:10.5409/wjcp.v15.i1.113925
Disproportionality Analysis of Linaclotide-Associated Adverse Events Using Individual case Safety Reports from the FDA Adverse Event Reporting System
Chen, M., Chen, Z., Xiong, Z., Guo, Q., Yang, Y., Shen, S., Wang, C., Zhu, Z., Wang, X., & Li, J. (2026) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-026-10480-7
“Clinical trials across phases II, III, and IIIB have demonstrated that lina-clotide effectively reduces the severity of constipation and improves intestinal and abdominal symptoms, with minimal serious adverse effects [10 , 21, 22].”
Efficacy and safety of six Chinese patent medicines for elderly functional constipation: a network meta-analysis
Wang, X., Wang, M., Liu, G., Zhong, R., Liu, L., Chen, Q., & Li, R. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1728217
“However, their use may be limited in certain patients due to the frequent occurrence of adverse reactions such as diarrhea, abdominal distension, nausea, and headache, as well as the relatively high cost of these medications (8, 9).”
Etude des perturbations de l'homéostasie intestinale en cas d'infection par citrobacter rodentium. Conséquences sur le bien-être de l'hôte
Baudu, E. (2018) · theses.fr (ABES) · doi:10.70675/42c7a86czd734z4a38zba45z18b45741ec10
Health potential of GABA-producing Lactococcus lactis strains : towards novel therapeutic strategies in visceral hypersensitivity management
Gomes, P. (2023) · theses.fr (ABES) · doi:10.70675/e62ef6fczef8az47c7za3b7ze3f8b24127a4
Konstipasiya ahıl və qoca insanların tibbi -sosial problemlərindən biri kimi
Çobanov, R., Hacıyeva, Y., & Yusufova, B. (2026) · İctimai sağlamlıq · doi:10.33864/3105-7020.2026.n1.4-13
Chronische Obstipation und obstruktives Defäkationssyndrom
Tatu, A. M. (2026) · Die Gastroenterologie · doi:10.1007/s11377-026-00997-1
Constipation with bloating: a clinical approach to evaluation and management
Cangemi, D. J., Laitman, A. P., Faiman, O., & Chang, B. W. (2026) · Annals of Medicine · doi:10.1080/07853890.2026.2684172
“[91,92,97,98] Guanylate cyclase-c agonist iBs-c; cic • significant improvement in bloating in both iBs-c and cic, including individuals with moderate to severe bloating at baseline lubiprostone [93,99] chloride channel activator iBs-c; cic • significant improvement in bloating in cic • improvement…”
Influential
Efficacy and safety of linaclotide plus polyethylene glycol for bowel preparation before colonoscopy in elderly Chinese patients: a systematic review and meta-analysis
Li, S. Y., Wei, H., Wang, J., Su, X. Y., Wu, Q., Wang, J., Peng, P., & Qin, M. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1833539
Efficacy and Safety of Linaclotide in Pediatric Patients of Functional Constipation: A Meta-analysis of Randomized Controlled Trials
Khan, M. S., Ahmed, H., Siddiqui, E., Khalid, M., Chandani, D. K., Naseer, H. W., & Abro, M. T. (2026) · Annals of Pharmacotherapy · doi:10.1177/10600280261479335
Effect of Age and Age‐Defined Menopausal Status on Linaclotide Efficacy and Safety in Adults With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation: Post Hoc Analyses of Phase 2b/3 Studies
Chang, L., Staller, K. D., Houghton, L. A., Yerneni, N., Higgins, S., Chen, W., Wu, J., Ford, A. C., Feuerstadt, P., & Brenner, D. M. (2026) · Neurogastroenterology & Motility · doi:10.1111/nmo.70429
Development and internal validation of a prediction model for suboptimal bowel preparation in individuals aged ≤50 years undergoing colonoscopy
Jiang, F., Chen, X., Wei, Z., Lin, S., Liu, L., Ma, P., Xiao, Y., & Fu, Z. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1939670
“More recently, adjunctive agents such as linaclotide have been evaluated as strategies to improve bowel preparation, particularly in patients with constipation (12, 13).”
Pelvic floor magnetic stimulation combined with biofeedback-based electrical stimulation for obstructed defecation syndrome: a retrospective cohort study
Tang, K., Zhang, R., Wang, K., Ding, R., Liu, W., Wang, E.-J., & Ming, L. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1982655

Authors: Lembo, A. J., Schneier, H. A., Shiff, S. J., Kurtz, C. B., MacDougall, J. E., Jia, X. D., Shao, J. Z., Lavins, B. J., Currie, M. G., Fitch, D. A., Jeglinski, B. I., Eng, P., Fox, S. M., & Johnston, J. M.
Affiliations: Beth Israel Deaconess Medical Center (US)
Forest Laboratories (United States) (US)
Ironwood Pharmaceuticals (United States) (US)
ORCID: Lembo, Anthony J.
Currie, Mark G.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2011-08-11
Volume: 365
Issue: 6
Pages: 527-536
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1010863
OpenAlex: W2129385409
Cited by: 373
References: 18
Citations by year: 2026: 16 · 2025: 12 · 2024: 28 · 2023: 22 · 2022: 19 · 2021: 23 · 2020: 23 · 2019: 20 · 2018: 31 · 2017: 24 · 2016: 32 · 2015: 26 · 2014: 26 · 2013: 40 · 2012: 25
FWCI: 31.44
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: Ironwood Pharmaceuticals, Incorporated
Topics: Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
Health Sciences › Medicine › Urology › Pelvic floor disorders treatments
Health Sciences › Medicine › Surgery › Congenital gastrointestinal and neural anomalies
Keywords: linaclotide, chronic constipation, spontaneous bowel movements, diarrhea, drug safety, treatment efficacy
MeSH terms: Adolescent, Adult, Aged, Aged, 80 and over, Chronic Disease, Constipation, Defecation, Diarrhea, Double-Blind Method, Female, Guanylate Cyclase, Humans, Male, Middle Aged, Peptides, Quality of Life, Withholding Treatment, Receptors, Guanylate Cyclase-Coupled, Laxatives, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Two Randomized Trials of Linaclotide for Chronic Constipation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks